Publications by authors named "Thomas E Hutson"

100Publications

Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches.

Cancer J 2020 Sep/Oct;26(5):441-447

Urologic Cancer Research and Treatment Center, Texas Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000474DOI Listing
September 2020

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.

Future Oncol 2020 Oct 21;16(28):2147-2164. Epub 2020 Jul 21.

Division of Genitourinary Oncology, Charles A Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, 3410 Worth Street STE 400, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0443DOI Listing
October 2020

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 12 6;17(6):425-435.e4. Epub 2019 Feb 6.

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518515PMC
December 2019

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Eur J Cancer 2018 05 20;94:87-94. Epub 2018 Mar 20.

Cambridge University Health Partners, R4 Block, Box 193, Cambridge Biomedical Campus, Hills Road, Cambridge, England, CB2 0QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774240PMC
May 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804841PMC
March 2018

New treatment options for metastatic renal cell carcinoma.

ESMO Open 2017 9;2(2):e000185. Epub 2017 May 9.

Medical Oncology Department, Algemeen Ziekenhuis Klina, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519813PMC
May 2017

Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.

Future Oncol 2017 Jun 9;13(15):1323-1332. Epub 2017 May 9.

Pfizer Outcomes & Evidence, 235 East 42nd St., New York, NY 10017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0566DOI Listing
June 2017

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Am Soc Clin Oncol Educ Book 2016 ;35:113-7

From the Texas A&M Health Science Center, Bryan TX; Baylor-Sammons Cancer Center, Dallas, TX; US Oncology, Texas Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158892DOI Listing
January 2017

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Lancet Oncol 2016 Jan 23;17(1):e4-5. Epub 2015 Dec 23.

Royal Marsden Hospital NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00543-4DOI Listing
January 2016

Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.

Future Oncol 2016 Feb 26;12(4):533-49. Epub 2015 Nov 26.

Texas Oncology, PA, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.313DOI Listing
February 2016

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

N Engl J Med 2014 May;370(18):1769-70

Memorial Sloan-Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1400731
Publisher Site
http://dx.doi.org/10.1056/NEJMc1400731DOI Listing
May 2014

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

J Clin Oncol 2014 03 2;32(8):760-7. Epub 2013 Dec 2.

Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569683PMC
March 2014

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

J Clin Oncol 2013 Oct 9;31(30):3791-9. Epub 2013 Sep 9.

Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Dmitry Nosov, N.N. Blokhin Cancer Research Center; Boris Y. Alekseev, Federal State Institution, Moscow Research Oncological Institute, Moscow; Oleg Lipatov, State Budget Medical Institution, Republican Clinical Oncological Center, Bashkortostan; Anna Alyasova, Federal Budget Medical Institution, Privolzhsky District Medical Center, Nizhny Novgorod; Mikhail Kogan, State Budget Higher Educational Institute, The Rostov State Medical University, Rostov-on-Don, Russia; Timothy Eisen, Cambridge University Health Partners, Cambridge, United Kingdom; Igor Bondarenko, Dnipropetrovsk State Medical Academy under the Ministry of Health of Ukraine, Dnipropetrovsk; Vladimir Lesovoy, V.I. Shapoval Regional Clinical Center for Urology and Nephrology, Kharkiv; Oleksiy Lyulko, Zaporizhia Medical Academy of Postgraduate Education, Zaporizhia, Ukraine; Piotr Tomczak, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznań; Cezary Szczylik, Military Institute of Health, Warsaw, Poland; Mihai Harza, Fundeni Clinical Institute, Bucharest, Romania; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; David Cella, Northwestern University Feinberg School of Medicine, Chicago; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; Cristina Ivanescu, Quintiles, Hoofddorp, the Netherlands; Brooke Esteves, Anna Berkenblit, Andrew Strahs, AVEO Oncology, Cambridge, MA; Thomas E. Hutson, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.4940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569677PMC
October 2013

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Clin Cancer Res 2013 Sep 23;19(18):5218-26. Epub 2013 Jul 23.

Authors' Affiliations: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts; GlaxoSmithKline, Collegeville, Pennsylvania; Memorial Sloan-Kettering Cancer Center, New York, New York; and Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522695PMC
September 2013

Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.

Cancer J 2013 Jul-Aug;19(4):307-10

Hematology and Oncology, Texas Oncology Fort Worth, Fort Worth, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31829d5d15DOI Listing
February 2014

Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.

Clin Genitourin Cancer 2013 Jun 12;11(2):115-20. Epub 2012 Oct 12.

Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731200183
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2012.09.008DOI Listing
June 2013

Difficulty in predicting survival in metastatic renal cancer.

Lancet Oncol 2012 Sep 8;13(9):859-60. Epub 2012 Aug 8.

Experiment Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London EC1A 7BE, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045127031
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(12)70318-2DOI Listing
September 2012

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

Eur Urol 2012 Feb 30;61(2):307-16. Epub 2011 Oct 30.

Texas Oncology and Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd., Webster, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2011.10.032DOI Listing
February 2012

Sunitinib rechallenge in metastatic renal cell carcinoma patients.

Cancer 2010 Dec 2;116(23):5400-6. Epub 2010 Nov 2.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.25583
Publisher Site
http://dx.doi.org/10.1002/cncr.25583DOI Listing
December 2010

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.

Onco Targets Ther 2010 Oct 5;3:147-55. Epub 2010 Oct 5.

Baylor-Sammons Cancer Center/Texas Oncology, PA, GU Oncology Program, Dallas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962303PMC
http://dx.doi.org/10.2147/ott.s12480DOI Listing
October 2010

Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.

Cancer 2011 Feb 4;117(4):752-7. Epub 2010 Oct 4.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25457DOI Listing
February 2011

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

Cancer 2010 Dec 30;116(23):5383-90. Epub 2010 Aug 30.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25327DOI Listing
December 2010

Sequential use of targeted agents in the treatment of renal cell carcinoma.

Crit Rev Oncol Hematol 2011 Jan 11;77(1):48-62. Epub 2010 Aug 11.

Baylor University Medical Center, Dallas, TX 75246, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2010.07.018DOI Listing
January 2011

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

Eur J Cancer 2010 Sep 23;46(13):2432-40. Epub 2010 Jul 23.

Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.06.121DOI Listing
September 2010

Molecularly targeted agents for renal cell carcinoma: the next generation.

Clin Adv Hematol Oncol 2010 May;8(5):357-60, 361-4

Genitourinary Oncology and Melanoma Program, Baylor University Medical Center, Sammons Cancer Center, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
May 2010

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Cancer 2010 Sep;116(18):4256-65

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25219DOI Listing
September 2010

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

Future Oncol 2010 May;6(5):665-79

Huntsman Cancer Institute, University of Utah, Salt Lake City, 2000 Circle of Hope, Ste 2123, UT 84117, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.48DOI Listing
May 2010

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

J Clin Oncol 2010 Jan 14;28(3):475-80. Epub 2009 Dec 14.

Baylor-Sammons/Texas Oncology Physician's Association, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.6994DOI Listing
January 2010

Pazopanib for the treatment of renal cell carcinoma and other malignancies.

Drugs Today (Barc) 2009 Sep;45(9):651-61

Texas Oncology, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/1396674/dot.2009.45.9.1414786DOI Listing
September 2009

Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma.

Clin Genitourin Cancer 2008 Dec;6 Suppl 1:S29-36

Texas Oncology, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cgc.2008.s.005DOI Listing
December 2008

Novel therapeutics for metastatic renal cell carcinoma.

Cancer 2009 May;115(10 Suppl):2361-7

Genitourinary Oncology Program, Baylor Sammons Cancer Center, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.24235
Publisher Site
http://dx.doi.org/10.1002/cncr.24235DOI Listing
May 2009

Patient selection for phase II trials.

Am J Clin Oncol 2009 Apr;32(2):216-9

Texas Oncology, P.A., Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e318172dccdDOI Listing
April 2009

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

Invest New Drugs 2010 Apr 6;28(2):194-8. Epub 2009 Mar 6.

Translational Oncology Program, US Oncology Research, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9239-3DOI Listing
April 2010

Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.

Authors:
Thomas E Hutson

Expert Rev Anticancer Ther 2008 Nov;8(11):1723-31

Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.ahead-of-printDOI Listing
November 2008

Experimental therapy for advanced renal cell carcinoma.

Expert Opin Investig Drugs 2008 Nov;17(11):1693-702

Baylor Sammons Cancer Center, Genitourinary Oncology Program, Texas Oncology, PA, Dallas, Texas 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.11.1693DOI Listing
November 2008

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

Oncologist 2008 Oct 6;13(10):1084-96. Epub 2008 Oct 6.

Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0120DOI Listing
October 2008

Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Clin Genitourin Cancer 2008 Sep;6(2):134-7

Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CGC.2008.n.023DOI Listing
September 2008

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Cancer 2008 Oct;113(7):1552-8

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23776DOI Listing
October 2008

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

J Clin Oncol 2008 Aug;26(22):3743-8

Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.5416DOI Listing
August 2008

Trial design for metastatic castration-resistant prostate cancer.

J Clin Oncol 2008 Jul;26(21):3647-8; author reply 3648-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.17.1140DOI Listing
July 2008

Axitinib for renal cell carcinoma.

Expert Opin Investig Drugs 2008 May;17(5):741-8

Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.5.741DOI Listing
May 2008

Renal cell carcinoma: what does the future hold?

Authors:
Thomas E Hutson

BJU Int 2008 Jul 2;102(1):5-6. Epub 2008 Apr 2.

Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2008.07632.xDOI Listing
July 2008

Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

Clin Genitourin Cancer 2007 Dec;5(7):457-9

US Oncology Research, Inc., 501 Medical Center Blvd, Webster, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CGC.2007.n.036DOI Listing
December 2007

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Expert Opin Investig Drugs 2008 Feb;17(2):253-61

Genitourinary Oncology Program, Texas Oncology, PA, US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.2.253DOI Listing
February 2008

Current optimal chemotherapy for advanced urothelial cancer.

Expert Rev Anticancer Ther 2008 Jan;8(1):51-61

US Oncology Research & Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.8.1.51DOI Listing
January 2008

Novel agents for muscle-invasive and advanced urothelial cancer.

BJU Int 2008 Apr 13;101(8):937-43. Epub 2007 Nov 13.

US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2007.07326.xDOI Listing
April 2008

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Cancer 2007 Dec;110(12):2628-39

Genitourinary Oncology Program, U.S. Oncology Research, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23085DOI Listing
December 2007

Evolving role of novel targeted agents in renal cell carcinoma.

Oncology (Williston Park) 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190

Baylor Sammons Cancer Center, U.S. Oncology Research Network Dallas, Texas, USA.

View Article

Download full-text PDF

Source
September 2007

Renal cell cancer.

Cancer J 2007 Sep-Oct;13(5):282-6

Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, and US Oncology Research Network, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318156fe69DOI Listing
January 2008

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.

Cancer Chemother Pharmacol 2008 Jul 2;62(2):347-54. Epub 2007 Oct 2.

Experimental Therapeutics Program, Department of Hematology and Medical Oncology/ R33, The Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0594-5DOI Listing
July 2008

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

Authors:
Thomas E Hutson

Expert Rev Anticancer Ther 2007 Sep;7(9):1193-202

Baylor University Medical Center, GU Oncology Program, Texas Oncology, PA, Sammons Cancer Center, 3535 Worth Street, Dallas TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.9.1193DOI Listing
September 2007

Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:
Thomas E Hutson

Proc (Bayl Univ Med Cent) 2007 Jul;20(3):244-8

Genitourinary Oncology Program, Department of Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906573PMC
http://dx.doi.org/10.1080/08998280.2007.11928297DOI Listing
July 2007

Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Curr Oncol Rep 2007 Mar;9(2):115-9

Texas Oncology, P. A., Baylor Sammons Cancer Center, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-007-0007-2DOI Listing
March 2007

Recent advances in the therapy of renal cancer.

Expert Opin Biol Ther 2007 Feb;7(2):233-42

US Oncology Research, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.7.2.233DOI Listing
February 2007